Cytokinetics, Inc.
Climate Impact & Sustainability Data (2022, 2023)
Reporting Period: 2022
Environmental Metrics
Total Carbon Emissions:1.50 metric kilotons CO2e
Scope 1 Emissions:0.67 metric kilotons CO2e
Scope 2 Emissions:0.83 metric kilotons CO2e
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:0.99484 million gallons
Waste Generated:273.0 tons (est.)
Carbon Intensity:Not disclosed
ESG Focus Areas
- Patient Centricity
- Diversity, Equity, Inclusion and Respect
- Environmental Sustainability
- Community Engagement
Environmental Achievements
- Initiated GHG emissions tracking, reporting Scope 1 and 2 emissions of 1.50 metric kilotons CO2e.
Social Achievements
- Achieved 100% compliance with Code of Conduct training.
- 52% year-over-year increase in diverse hiring.
- Launched the Cytokinetics EmpowHERment Network, an employee resource group.
- Maintained a low employee turnover rate of 9%.
Governance Achievements
- Established a cross-functional Responsibility Committee to manage ESG strategy and execution.
- Board of Directors includes 30% women and 90% independent directors.
- Implemented a holistic cybersecurity program.
Climate Goals & Targets
Long-term Goals:
- Not disclosed
Medium-term Goals:
- Not disclosed
Short-term Goals:
- Further reduce GHG emissions and energy use.
Environmental Challenges
- Addressing inequities in healthcare access for underserved patient populations, particularly Black patients with heart failure.
- Ensuring patient diversity in clinical trials.
Mitigation Strategies
- Identifying partnerships for education and awareness to improve access to treatment for underserved heart failure patients.
- Investing in equipment rentals for clinical trial centers lacking modern technology to improve patient screening and inclusion.
Supply Chain Management
Supplier Audits: Not disclosed
Responsible Procurement
- Dual-sourcing initiative to reduce supply chain risk.
- Collaboration with suppliers sharing Cytokinetics' values (patient centricity, environmental consciousness, community involvement, DEIR).
Climate-Related Risks & Opportunities
Physical Risks
- Not disclosed
Transition Risks
- Not disclosed
Opportunities
- Not disclosed
Reporting Standards
Frameworks Used: GRI, SASB, TCFD
Certifications: LEED Gold (Headquarters building)
Third-party Assurance: Not disclosed
UN Sustainable Development Goals
- Not disclosed
Not disclosed
Sustainable Products & Innovation
- Not disclosed
Awards & Recognition
- Great Place to Work certification
- Fortune magazine's “Best Workplace in BioPharma” and “Best Workplace in the Bay Area”
- San Francisco Business Times' “Best Place to Work”
Reporting Period: 2023
Environmental Metrics
Total Carbon Emissions:1230 metric kilotons CO2e
Scope 1 Emissions:391 metric kilotons CO2e
Scope 2 Emissions:839 metric kilotons CO2e
Renewable Energy Share:Nearly 50%
Total Energy Consumption:4509 MWh
Water Consumption:1.488 million gallons
Waste Generated:87.60 tons (non-hazardous); 18.36 tons (hazardous)
Carbon Intensity:2.97 tCO2e/employee (Scopes 1 & 2)
ESG Focus Areas
- Patient Centricity
- Diversity, Equity, Inclusion, and Respect
- Environmental Sustainability
- Community Engagement
Environmental Achievements
- Scope 1 and 2 GHG emissions decreased by 20% compared to 2022
- Achieved nearly 50% renewable electricity use in Cytokinetics facilities
- Launched a new office waste management program aiming to reduce landfill waste by up to 75%.
Social Achievements
- Developed a Patient Centricity Playbook with guidelines to harmonize patient-centric approach.
- Partnered with The National Black Church Initiative (NBCI) to launch Heart First educational program.
- Workforce diversity increased with 51% of employees identifying as one or more underrepresented group (5% increase from 2022).
- Launched a new talent learning platform (Thrive) to support employee growth and development.
- Employee engagement survey achieved an 82% score with 95% participation.
Governance Achievements
- 100% of employees trained on the Code of Ethics and Business Conduct.
- Published Anti-Corruption and Anti-Bribery and Data Privacy Policies.
- Maintained 39% women in senior leadership (VP and above).
- Achieved 29% underrepresented groups in senior leadership (VP and above).
Climate Goals & Targets
Short-term Goals:
- Reduce landfill waste by up to 75% over the next few years.
Environmental Challenges
- Regulatory and clinical setbacks for some late-stage potential medicines.
- Need to increase diversity in clinical trials.
Mitigation Strategies
- Developed action plans to support corporate responsibility objectives and goals.
- Implemented multiple community outreach initiatives to increase diversity in clinical trials.
- Expanded activities globally to attract patients of multiple ethnicities.
Supply Chain Management
Responsible Procurement
- Commitment to patient centricity, environmental and energy consciousness, community involvement, diversity, equity, inclusion and respect.
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: SASB
Awards & Recognition
- Great Place to Work (2023)
- Fortune magazine’s “Best Workplace in BioPharma” and “Best Workplace in the Bay Area” (2022 and 2023)
- San Francisco Business Times’ “Best Place to Work in the Bay Area” (2021, 2022, and 2023)
- San Francisco Business Times’ “Winner in Wellness” award (2023)